Oxybutynin and Omega-3 for OAB (Overactive Bladder)

Summary

We aim to evaluate whether the addition of Omega-3 fatty acids to oxybutynin, a standard first-line treatment for overactive bladder syndrome, will improve symptoms and quality of life. Secondarily, we will evaluate whether Omega-3 fatty acids help reduce the adverse effects of oxybutynin. Hypothesis * Primary: Omega-3 will enhance the beneficial role of oxybutynin in the treatment of overactive bladder (OAB) * Secondary: Omega-3 will reduce the side effects of dry eyes and constipation associated with oxybutynin

Timeline

Start

2014-02

Primary completion

2015-09

Completion

2015-09

Drugs

Indications